<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="ctm270153" xml:lang="en" article-type="article-commentary"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Transl Med</journal-id><journal-id journal-id-type="iso-abbrev">Clin Transl Med</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2001-1326</journal-id><journal-id journal-id-type="publisher-id">CTM2</journal-id><journal-title-group><journal-title>Clinical and Translational Medicine</journal-title></journal-title-group><issn pub-type="epub">2001-1326</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39731353</article-id><article-id pub-id-type="pmc">PMC11681005</article-id><article-id pub-id-type="doi">10.1002/ctm2.70153</article-id><article-id pub-id-type="publisher-id">CTM270153</article-id><article-categories><subj-group subj-group-type="overline"><subject>Letter to the Journal</subject></subj-group><subj-group subj-group-type="heading"><subject>Letter to the Journal</subject></subj-group></article-categories><title-group><article-title>Concurrent DNA hypomethylation and epigenomic reprogramming driven by androgen receptor binding in bladder cancer oncogenesis</article-title><alt-title alt-title-type="left-running-head">XIAO <sc>et&#x000a0;al</sc>.</alt-title></title-group><contrib-group><contrib id="ctm270153-cr-0001" contrib-type="author"><name><surname>Xiao</surname><given-names>Yu</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1377-9685</contrib-id><xref rid="ctm270153-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="ctm270153-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="ctm270153-note-0001" ref-type="author-notes">
<sup>#</sup>
</xref></contrib><contrib id="ctm270153-cr-0002" contrib-type="author"><name><surname>Ju</surname><given-names>Lingao</given-names></name><xref rid="ctm270153-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="ctm270153-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="ctm270153-note-0001" ref-type="author-notes">
<sup>#</sup>
</xref></contrib><contrib id="ctm270153-cr-0003" contrib-type="author"><name><surname>Jin</surname><given-names>Wan</given-names></name><xref rid="ctm270153-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="ctm270153-aff-0004" ref-type="aff">
<sup>4</sup>
</xref><xref rid="ctm270153-note-0001" ref-type="author-notes">
<sup>#</sup>
</xref></contrib><contrib id="ctm270153-cr-0004" contrib-type="author"><name><surname>Peng</surname><given-names>Hongwei</given-names></name><xref rid="ctm270153-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="ctm270153-cr-0005" contrib-type="author"><name><surname>Zhou</surname><given-names>Zongning</given-names></name><xref rid="ctm270153-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="ctm270153-cr-0006" contrib-type="author"><name><surname>Yu</surname><given-names>Mengxue</given-names></name><xref rid="ctm270153-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="ctm270153-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="ctm270153-cr-0007" contrib-type="author"><name><surname>Xu</surname><given-names>Zilin</given-names></name><xref rid="ctm270153-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="ctm270153-cr-0008" contrib-type="author"><name><surname>Wang</surname><given-names>Gang</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4690-9020</contrib-id><xref rid="ctm270153-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="ctm270153-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="ctm270153-cr-0009" contrib-type="author" corresp="yes"><name><surname>Qian</surname><given-names>Kaiyu</given-names></name><xref rid="ctm270153-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="ctm270153-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><address><email>qky1009@whu.edu.cn</email></address></contrib><contrib id="ctm270153-cr-0010" contrib-type="author" corresp="yes"><name><surname>Zhang</surname><given-names>Yi</given-names></name><xref rid="ctm270153-aff-0004" ref-type="aff">
<sup>4</sup>
</xref><xref rid="ctm270153-aff-0005" ref-type="aff">
<sup>5</sup>
</xref><xref rid="ctm270153-note-0002" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><address><email>zy@eulertechnology.com</email></address></contrib><contrib id="ctm270153-cr-0011" contrib-type="author" corresp="yes"><name><surname>Wang</surname><given-names>Xinghuan</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3497-0024</contrib-id><xref rid="ctm270153-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="ctm270153-aff-0006" ref-type="aff">
<sup>6</sup>
</xref><xref rid="ctm270153-aff-0007" ref-type="aff">
<sup>7</sup>
</xref><address><email>wangxinghuan@whu.edu.cn</email></address></contrib></contrib-group><aff id="ctm270153-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Urology</named-content>
<institution>Zhongnan Hospital of Wuhan University</institution>
<city>Wuhan</city>
<country country="CN">China</country>
</aff><aff id="ctm270153-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Biological Repositories</named-content>
<named-content content-type="organisation-division">Human Genetic Resources Preservation Center of Hubei Province</named-content>
<institution>Zhongnan Hospital of Wuhan University</institution>
<city>Wuhan</city>
<country country="CN">China</country>
</aff><aff id="ctm270153-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Hubei Key Laboratory of Urological Diseases</named-content>
<named-content content-type="organisation-division">Laboratory of Precision Medicine</named-content>
<institution>Zhongnan Hospital of Wuhan University</institution>
<city>Wuhan</city>
<country country="CN">China</country>
</aff><aff id="ctm270153-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Euler Technology</named-content>
<institution>ZGC Life Sciences Park</institution>
<city>Beijing</city>
<country country="CN">China</country>
</aff><aff id="ctm270153-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">High Performance Computing Center</named-content>
<named-content content-type="organisation-division">the Peking&#x02010;Tsinghua College of Life Sciences</named-content>
<institution>Peking University</institution>
<city>Beijing</city>
<country country="CN">China</country>
</aff><aff id="ctm270153-aff-0006">
<label>
<sup>6</sup>
</label>
<named-content content-type="organisation-division">Wuhan Research Center for Infectious Diseases and Cancer</named-content>
<institution>Chinese Academy of Medical Sciences</institution>
<city>Wuhan</city>
<country country="CN">China</country>
</aff><aff id="ctm270153-aff-0007">
<label>
<sup>7</sup>
</label>
<named-content content-type="organisation-division">Medical Research Institute</named-content>
<named-content content-type="organisation-division">Frontier Science Center for Immunology and Metabolism</named-content>
<named-content content-type="organisation-division">Taikang Center for Life and Medical Sciences</named-content>
<institution>Wuhan University</institution>
<city>Wuhan</city>
<country country="CN">China</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence</bold>
<break/>Kaiyu Qian, Department of Biological Repositories, Human Genetic Resources Preservation Center of Hubei Province, Zhongnan Hospital of Wuhan University, Wuhan, China.<break/> Email: <email>qky1009@whu.edu.cn</email>
<break/>Yi Zhang, Euler Technology, ZGC Life Sciences Park, Beijing, China.<break/> Email: <email>zy@eulertechnology.com</email>
<break/>Xinghuan Wang, Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China.<break/> Email: <email>wangxinghuan@whu.edu.cn</email>
<break/>
</corresp><fn id="ctm270153-note-0001" fn-type="equal"><label>#</label><p>These authors contributed equally to this work.</p></fn><fn id="ctm270153-note-0002"><label>&#x02020;</label><p>Lead contact.</p></fn></author-notes><pub-date pub-type="epub"><day>27</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>1</month><year>2025</year></pub-date><volume>15</volume><issue seq="50">1</issue><issue-id pub-id-type="doi">10.1002/ctm2.v15.1</issue-id><elocation-id>e70153</elocation-id><history>
<date date-type="rev-recd"><day>05</day><month>12</month><year>2024</year></date>
<date date-type="received"><day>01</day><month>11</month><year>2024</year></date>
<date date-type="accepted"><day>17</day><month>12</month><year>2024</year></date>
</history><permissions><!--&#x000a9; 2025 Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.--><copyright-statement content-type="article-copyright">&#x000a9; 2024 The Author(s). <italic toggle="yes">Clinical and Translational Medicine</italic> published by John Wiley &#x00026; Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:CTM2-15-e70153.pdf"/><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>National Natural Science Foundation of China
</institution><institution-id institution-id-type="doi">10.13039/501100001809</institution-id></institution-wrap></funding-source><award-id>82472733</award-id></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>Fundamental Research Funds for the Central Universities
</institution><institution-id institution-id-type="doi">10.13039/501100012226</institution-id></institution-wrap></funding-source><award-id>2042022dx0003</award-id></award-group><award-group id="funding-0003"><funding-source>Research Fund of Zhongnan Hospital of Wuhan University</funding-source><award-id>YYXKNLJS2024001</award-id><award-id>PTPP2024001</award-id></award-group></funding-group><counts><fig-count count="2"/><table-count count="0"/><page-count count="5"/><word-count count="2182"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>January 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.1 mode:remove_FC converted:28.12.2024</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="ctm270153-cit-0011">
<string-name>
<surname>Xiao</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Ju</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Jin</surname>
<given-names>W</given-names>
</string-name>, et&#x000a0;al. <article-title>Concurrent DNA hypomethylation and epigenomic reprogramming driven by androgen receptor binding in bladder cancer oncogenesis</article-title>. <source>Clin Transl Med</source>. <year>2025</year>;<volume>15</volume>:<elocation-id>e70153</elocation-id>. <pub-id pub-id-type="doi">10.1002/ctm2.70153</pub-id>
</mixed-citation>
</p></notes></front><body><sec sec-type="opening-section" id="ctm270153-sec-0010"><label>1</label><p>The intratumor heterogeneity (ITH) of bladder cancer (BLCA) facilitates resistance to treatment and enables evasion of immune surveillance, directly impacting patient outcomes and clinical prognosis. Our group has newly developed a tool named EpiTrace, which enables tracking single&#x02010;cell (sc) evolution via chromatin accessibility<xref rid="ctm270153-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> and reveals the ITH of bladder cancer in all stages.<xref rid="ctm270153-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> We also found that the TM4SF1&#x02010;positive cancer subpopulation (TPCS) drives ITH diversification in BLCA via integrative single&#x02010;cell atlas analysis.<xref rid="ctm270153-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>
</p><p>Previous data suggest that Notch signalling might contribute to urothelium cell lineage specification.<xref rid="ctm270153-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> Compared with that in normal urothelium cells and other cancer cells, the RNA expression of HES1 and HES4, effectors of Notch signalling, at the single&#x02010;cell level is significantly lower in TPCS.<xref rid="ctm270153-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> As ASCL1/2 expression is difficult to assess via single&#x02010;cell RNA sequencing because of the low expression abundance resulting from the repression of the Notch signal, we used single&#x02010;cell assay for transposase&#x02010;accessible chromatin (scATAC) data to infer their transcriptional activity. Compared with those in other cells, scATAC&#x02010;inferred HES1 and HES4 expression levels were decreased in TPCS. In contrast, ASCL1 and ASCL2 transcription factors (TFs) activities are increased in TPCS without apparent transcriptional upregulation (Figure&#x000a0;<xref rid="ctm270153-fig-0001" ref-type="fig">1A</xref>), suggesting derepression of ASCL1/2 from HES1/4. In accordance with the results of the cell&#x02010;cell signalling analysis and coregulated transcription network activity, SMAD4 transcription activity was increased, whereas its RNA level did not change (Figure&#x000a0;<xref rid="ctm270153-fig-0001" ref-type="fig">1A</xref>). A change in transcription factor activity was also noted for other TFs, including FOXA1 (Figure&#x000a0;<xref rid="ctm270153-fig-0001" ref-type="fig">1A</xref> and Figures <xref rid="ctm270153-supinfo-0001" ref-type="">S1 and S2</xref>).</p><fig position="float" fig-type="FIGURE" id="ctm270153-fig-0001"><label>FIGURE 1</label><caption><p>Androgen receptor (AR) binding reprogrammed enhancers epigenetically in TM4SF1&#x02010;positive cancer subpopulation (TPCS). (A) Transcription factor binding activity (z) and expression (Exp) of HES1, HES4, ASCL1, ASCL2, SMAD4 and FOXA1 in normal cells, luminal cancer cells, basal cancer cells, and TPCS from scATAC data. (B) Cleavage under target &#x00026; tagmentation (CUT&#x00026;Tag) profiling of AR&#x02010;binding, FOXA1&#x02010;binding, and H3K4me3, H3K27me3 and H3K27ac histone modifications in a basal cell line (5637, B) and a luminal cell line (RT4, L). Muscle&#x02010;invasive bladder cancer (MIBC)&#x02010;specific hypomethylated genomic loci are shown in the figure. Loci were K&#x02010;means clustered according to their epigenetic modification profiles into 10 clusters. Because the 10th cluster lacked any meaningful epigenetic modifications in this assay, their binding profile is not shown in the figure. Regulatory element annotations of the clusters are shown in the left panel. CUT&#x00026;Tag signals are shown on the right panel. Cluster annotations according to their genomic location as well as histone modifications are shown in colored bars next to the CUT&#x00026;Tag panel (labels at the bottom). The <italic toggle="yes">HES4</italic>, <italic toggle="yes">GPX4</italic> and <italic toggle="yes">YWHAZ</italic> genes are in the 7th cluster (hypoC7), which is a set of enhancers that are lost in basal cells. (C) CUT&#x00026;Tag profiling of MIBC&#x02010;specific hypermethylated genomic loci. The labels are similar to those in B). (D) Single&#x02010;cell ATAC coverage of the hypoC3 cluster, which binds to FOXA1 in both basal and luminal cells but loses H3K27ac modification and AR binding in basal cells (red box in B). (E) Single&#x02010;cell ATAC coverage of the hypoC7 cluster, which lacks H3K27ac and is bound by FOXA1 in basal cells.</p></caption><graphic xlink:href="CTM2-15-e70153-g002" position="anchor" id="jats-graphic-1"/></fig><p>Elucidating the underlying molecular mechanisms for HES1 and HES4 repression requires the interrogation of the epigenetic information of both TPCS&#x02010;like and less malignant cancer cells. FOXA1 is known to be a master pioneering factor that is differentially expressed in muscle&#x02010;invasive bladder cancer (MIBC) downstream of BMP signalling and determines tumour phenotype.<xref rid="ctm270153-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> In prostate cancer, androgen receptor (AR) directly interacts with FOXA1, driving cancer growth and survival.<xref rid="ctm270153-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> BLCA incidence is 3&#x02013;4 times higher in males<xref rid="ctm270153-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="ctm270153-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>; however, when diagnosed with BLCA, women tend to present with more advanced disease stages compared to men, resulting in poorer treatment outcomes and higher mortality rates.<xref rid="ctm270153-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="ctm270153-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> Emerging research suggests that AR may facilitate the occurrence, progression, and recurrence of BLCA, potentially leading to the observed sex disparities.<xref rid="ctm270153-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> Therefore, we investigated how FOXA1 and AR binding epigenetically reprograms enhancers in BLCA epigenetically reprograms enhancers in BLCA.</p><p>We chose two cell lines for analysis: the RT4 cells with the TACC3&#x02010;FGFR3 fusion as a less malignant luminal&#x02010;like BLCA (Luminal, L) and the 5637 cells with homozygous TP53 mutation and amplified ERBB2 as an aggressive and malignant human muscle&#x02010;invasive BLCA (Basal, B) (Figures&#x000a0;<xref rid="ctm270153-fig-0001" ref-type="fig">1B,C</xref> and&#x000a0;<xref rid="ctm270153-fig-0002" ref-type="fig">2</xref>, and Dataset S1). Notably, as 5637 cells expressed high levels of KRT6A/B, we considered them basal&#x02010;like cell lines that mimic TPCS. By reanalyzing publicly available datasets and comparing them with our in&#x02010;house cleavage under target &#x00026; tagmentation (CUT&#x00026;Tag) data, we confirm that the quality of our CUT&#x00026;Tag sequencing is equivalent to that of previously reported datasets (Figures <xref rid="ctm270153-supinfo-0001" ref-type="">S3&#x02013;S5</xref>). We enriched known transcription factor&#x02010;binding site motifs in the RT4 AR peaks. As a control, we performed similar enrichment with the reference prostate cancer AR peaks (GSE70079). The enrichment results revealed that AR binding motifs were enriched in both datasets. However, the top enriched motif in both datasets was FOXA1 instead of AR, suggesting that AR binding to DNA is partially mediated by other transcription factors (Figure <xref rid="ctm270153-supinfo-0001" ref-type="">S6</xref>).</p><fig position="float" fig-type="FIGURE" id="ctm270153-fig-0002"><label>FIGURE 2</label><caption><p>Differential epigenomic reprogramming in bladder cancer (BLCA) related to androgen receptor (AR). (A, B) Top&#x02010;to&#x02010;bottom: AR cleavage under target &#x00026; tagmentation (CUT&#x00026;Tag) in RT4 cells (two antibodies), AR CUT&#x00026;Tag in 5637 cells (two antibodies), CTCF CUT&#x00026;Tag in RT4 cells, CTCF CUT&#x00026;Tag in 5637 cells, H3K4me3 CUT&#x00026;Tag in RT4 cells, H3K4me3 CUT&#x00026;Tag in 5637 cells, H3K27ac CUT&#x00026;Tag in RT4 cells, H3K27ac CUT&#x00026;Tag in 5637 cells, H3K27me3 CUT&#x00026;Tag in RT4 cells and H3K27me3 CUT&#x00026;Tag in 5637 cells. (A) Differential AR binding to the CD44 locus between RT4 and 5637 cells. (B) Differential AR binding to the TACC&#x02010;FGFR region in RT4 and 5637 cells. (C) AR binding profile across binding peaks in RT4 and 5637 cells.</p></caption><graphic xlink:href="CTM2-15-e70153-g001" position="anchor" id="jats-graphic-3"/></fig><p>In particular, the patterns of these transcription factors and histone modifications were used to demarcate different classes of chromatin states in tumour&#x02010;associated differentially methylated regions (DMRs) (hypoDMRs and hyperDMRs). These chromatin state classes were correlated with chromatin accessibility (ChrAcc) in single cancer cells derived from clinical samples. The hypoDMRs and hyperDMRs in MIBC were stratified into subgroups by utilizing profiles of histone modifications and transcription factor binding. These subgroups were annotated based on their histone modifications and genomic position information. MIBC&#x02010;specific hypoDMRs were divided into 10 clusters via k&#x02010;means clustering, with the first 9 clusters showing histone modifications on either AR, FOXA1, H3K4me3, H3K27ac or H3K27me3 (Figure&#x000a0;<xref rid="ctm270153-fig-0001" ref-type="fig">1B</xref>). The 10<sup>th</sup> cluster showed no signal for any of these modifications and was not analyzed in this study. In TPCS, MIBC&#x02010;hypoDMR group 3 (hypoC3), an enhancer cluster, exhibited a decrease in AR binding, as well as H3K27ac modification (Figure&#x000a0;<xref rid="ctm270153-fig-0001" ref-type="fig">1B</xref>). MIBC&#x02010;hypoDMR group 7 (hypoC7), which is located proximal to several basal&#x02010;low genes, such as <italic toggle="yes">GPX4</italic> and <italic toggle="yes">YWHAZ</italic>, presented increased H3K4me3 and FOXA1 binding and decreased H3K27ac in TPCS (Figure&#x000a0;<xref rid="ctm270153-fig-0001" ref-type="fig">1B</xref>). The ChrAcc of single BLCA cells in hypoC3 and hypoC7 increased in basal cancer cells relative to luminal cancer cells and further increased in TPCS (Figure&#x000a0;<xref rid="ctm270153-fig-0001" ref-type="fig">1D,E</xref>).</p><p>In the hyperDMR sets, MIBC&#x02010;hyperDMR group 8 (hyperC8) comprised FOXA1&#x02010;bound, H3K27ac/H3K4me3&#x02010;high enhancers (Figure&#x000a0;<xref rid="ctm270153-fig-0001" ref-type="fig">1C</xref>). Moreover, MIBC&#x02010;hyperDMR group 6 (hyperC6) comprises promoters that are solely active in basal cancer cells (Figure&#x000a0;<xref rid="ctm270153-fig-0001" ref-type="fig">1C</xref>) and that regulate lineage specification genes, such as <italic toggle="yes">HOXA3</italic>/<italic toggle="yes">HOXA5</italic>, which are upregulated in normal Bs2/3 cells.<xref rid="ctm270153-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> These results suggest that DNA hypermethylation might not necessarily be transcriptionally suppressive. Similarly, we observed that DNA hypermethylation at the SOX2 locus is linked to its overexpression in basal cancer.<xref rid="ctm270153-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> Additionally, other loci that exhibited differential methylation in MIBC exhibited basal cancer&#x02010;specific H3K27me3 deposition, indicating regulation via PRC2&#x02010;dependent mechanisms.</p><p>Alterations in the epigenomic landscape of TPCS have a direct effect on the expression of genes. In T3 and T4a clinical samples enriched with TPCS, DNA demethylation in a region bound by FOXA1 and CTCF downstream of <italic toggle="yes">HES4</italic> was associated with the loss of long&#x02010;range chromatin interactions, loss of enhancer activity, and gain of repressive H3K27me3 marks around the HES4 locus (Figure <xref rid="ctm270153-supinfo-0001" ref-type="">S7A,C</xref>). Similarly, differential FOXA1 binding and <italic toggle="yes">de novo</italic> DNAm were associated with increased interaction between FOXA1&#x02010;bound active enhancers and the promoter of <italic toggle="yes">TFAP2C</italic> in TPCS (Figure <xref rid="ctm270153-supinfo-0001" ref-type="">S7B,D</xref>). Differential AR binding is also linked to lineage&#x02010;specific gene expression (Figure&#x000a0;<xref rid="ctm270153-fig-0002" ref-type="fig">2</xref>).</p><p>Taken together, our results suggest that during BLCA oncogenesis, AR binding reprogrammed DNA hypomethylation occurs concomitantly with epigenomic patterning to control specific transcription programs, which may drive the evolutionary heterogeneity of MIBC.</p></sec><sec id="ctm270153-sec-0020"><title>AUTHOR CONTRIBUTIONS</title><p>Y.X., K.Q., Y.Z. and X.W. conceived and designed the study. Y.X., W.J., K.Q., and Y.Z. contributed to methodology. W.J. and Y.Z. performed computation and formal analysis. Y.X., L.J., W.J., G.W., K.Q. and Y.Z. performed the experiments and investigations. L.J., H.P., Z.Z., M.Y., Z.X., G.W., K.Q. and X.W. contributed to collecting and obtaining the study resources. Y.X., L.J., W.J. and Y.Z. wrote the manuscript. K.Q., Y.Z. and X.W. contributed to a critical review of the manuscript. All authors read and approved the final manuscript.</p></sec><sec sec-type="COI-statement" id="ctm270153-sec-0040"><title>CONFLICT OF INTEREST STATEMENT</title><p>The authors declared no conflict of interest.</p></sec><sec id="ctm270153-sec-0050"><title>FUNDING INFORMATION</title><p>This study was supported by the National Natural Science Foundation of China (82472733), the Fundamental Research Funds for the Central Universities (2042022dx0003) and the Research Fund of Zhongnan Hospital of Wuhan University (YYXKNLJS2024001 and PTPP2024001).</p></sec><sec id="ctm270153-sec-0080"><title>ETHICS STATEMENT</title><p>All research procedures were approved by the Institutional Review Board of the Zhongnan Hospital of Wuhan University (approval numbers: 2015029 and 2020102) and conducted in accordance with the Declaration of Helsinki. Informed consent was obtained from all subjects.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="ctm270153-supinfo-0001" position="float" content-type="local-data"/><supplementary-material id="ctm270153-supitem-0001" position="float" content-type="local-data"><caption><p>Supporting Information</p></caption><media xlink:href="CTM2-15-e70153-s002.pdf"/></supplementary-material><supplementary-material id="ctm270153-supitem-0002" position="float" content-type="local-data"><caption><p>Supporting Information</p></caption><media xlink:href="CTM2-15-e70153-s001.xlsx"/></supplementary-material></sec></body><back><ack id="ctm270153-sec-0030"><title>ACKNOWLEDGEMENTS</title><p>The excellent technical assistance of Danni Shan, Shanshan Zhang, Cong Zou, Wen Chen, and Wan Xiang at Zhongnan Hospital of Wuhan University is gratefully acknowledged.</p></ack><sec sec-type="data-availability" id="ctm270153-sec-0070"><title>DATA AVAILABILITY STATEMENT</title><p>The sequencing data of human bladder cancer biospecimens used in this study were derived from our previous publication.<xref rid="ctm270153-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> The remaining data are available within the article or Supporting Information.</p></sec><ref-list id="ctm270153-bibl-0001"><title>REFERENCES</title><ref id="ctm270153-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="ctm270153-cit-0001">
<string-name>
<surname>Xiao</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Jin</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Ju</surname>
<given-names>L</given-names>
</string-name>, et&#x000a0;al. <article-title>Tracking single&#x02010;cell evolution using clock&#x02010;like chromatin accessibility loci [published online ahead of print May 9, 2024]</article-title>. <source>Nat Biotechnol</source>. doi:<pub-id pub-id-type="doi">10.1038/s41587-024-02241-z</pub-id>
</mixed-citation></ref><ref id="ctm270153-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="ctm270153-cit-0002">
<string-name>
<surname>Xiao</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Jin</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Qian</surname>
<given-names>K</given-names>
</string-name>, et&#x000a0;al. <article-title>Integrative single cell atlas revealed intratumoral heterogeneity generation from an adaptive epigenetic cell state in human bladder urothelial carcinoma</article-title>. <source>Adv Sci</source>. <year>2024</year>;<volume>11</volume>(<issue>24</issue>):<elocation-id>e2308438</elocation-id>.</mixed-citation></ref><ref id="ctm270153-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="ctm270153-cit-0003">
<string-name>
<surname>Kim</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Choi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kang</surname>
<given-names>B</given-names>
</string-name>, et&#x000a0;al. <article-title>Creation of bladder assembloids mimicking tissue regeneration and cancer</article-title>. <source>Nature</source>. <year>2020</year>;<volume>588</volume>(<issue>7839</issue>):<fpage>664</fpage>&#x02010;<lpage>669</lpage>.<pub-id pub-id-type="pmid">33328632</pub-id>
</mixed-citation></ref><ref id="ctm270153-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="ctm270153-cit-0004">
<string-name>
<surname>Teng</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Zhou</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Cai</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Lupien</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>He</surname>
<given-names>HH</given-names>
</string-name>. <article-title>Pioneer of prostate cancer: past, present and the future of FOXA1</article-title>. <source>Protein Cell</source>. <year>2021</year>;<volume>12</volume>(<issue>1</issue>):<fpage>29</fpage>&#x02010;<lpage>38</lpage>.<pub-id pub-id-type="pmid">32946061</pub-id>
</mixed-citation></ref><ref id="ctm270153-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="ctm270153-cit-0005">
<string-name>
<surname>Dobruch</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Daneshmand</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Fisch</surname>
<given-names>M</given-names>
</string-name>, et&#x000a0;al. <article-title>Gender and bladder cancer: a collaborative review of etiology, biology, and outcomes</article-title>. <source>Eur Urol</source>. <year>2016</year>;<volume>69</volume>(<issue>2</issue>):<fpage>300</fpage>&#x02010;<lpage>310</lpage>.<pub-id pub-id-type="pmid">26346676</pub-id>
</mixed-citation></ref><ref id="ctm270153-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="ctm270153-cit-0006">
<string-name>
<surname>Safiri</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kolahi</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>Naghavi</surname>
<given-names>M</given-names>
</string-name>, <collab collab-type="authors">Global Burden of Disease Bladder Cancer Collaborators</collab>
. <article-title>Global, regional and national burden of bladder cancer and its attributable risk factors in 204 countries and territories, 1990&#x02013;2019: a systematic analysis for the Global Burden of Disease study 2019</article-title>. <source>BMJ Glob Health</source>. <year>2021</year>;<volume>6</volume>(<issue>11</issue>):<elocation-id>e004128</elocation-id>.</mixed-citation></ref><ref id="ctm270153-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="ctm270153-cit-0007">
<string-name>
<surname>Radkiewicz</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Edgren</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Johansson</surname>
<given-names>ALV</given-names>
</string-name>, et&#x000a0;al. <article-title>Sex differences in urothelial bladder cancer survival</article-title>. <source>Clin Genitourin Cancer</source>. <year>2020</year>;<volume>18</volume>(<issue>1</issue>):<fpage>26</fpage>&#x02010;<lpage>34.e6</lpage>.<pub-id pub-id-type="pmid">31787542</pub-id>
</mixed-citation></ref><ref id="ctm270153-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="ctm270153-cit-0008">
<string-name>
<surname>Hyldgaard</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Jensen</surname>
<given-names>JB</given-names>
</string-name>. <article-title>The inequality of females in bladder cancer</article-title>. <source>APMIS</source>. <year>2021</year>;<volume>129</volume>(<issue>12</issue>):<fpage>694</fpage>&#x02010;<lpage>699</lpage>.<pub-id pub-id-type="pmid">34582047</pub-id>
</mixed-citation></ref><ref id="ctm270153-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="ctm270153-cit-0009">
<string-name>
<surname>Chen</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>CP</given-names>
</string-name>, <string-name>
<surname>Quan</surname>
<given-names>C</given-names>
</string-name>, et&#x000a0;al. <article-title>The androgen receptor in bladder cancer</article-title>. <source>Nat Rev Urol</source>. <year>2023</year>;<volume>20</volume>(<issue>9</issue>):<fpage>560</fpage>&#x02010;<lpage>574</lpage>.<pub-id pub-id-type="pmid">37072491</pub-id>
</mixed-citation></ref><ref id="ctm270153-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="ctm270153-cit-0010">
<string-name>
<surname>Xiao</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Ju</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Qian</surname>
<given-names>K</given-names>
</string-name>, et&#x000a0;al. <article-title>Non&#x02010;invasive diagnosis and surveillance of bladder cancer with driver and passenger DNA methylation in a prospective cohort study</article-title>. <source>Clin Transl Med</source>. <year>2022</year>;<volume>12</volume>(<issue>8</issue>):<elocation-id>e1008</elocation-id>.<pub-id pub-id-type="pmid">35968916</pub-id>
</mixed-citation></ref></ref-list></back></article>